Heterocyclic Compounds for Targeted mGluR7 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological, psychiatric, otic, pain, visual, and gastrointestinal disorders related to glutamate dysfunction lack effective modulators of the metabotropic glutamate receptor subtype 7 (mGluR7), which are crucial for addressing these conditions.
Innovation Solution
Development of novel heterocyclic compounds that act as modulators, specifically targeting mGluR7, including iso-, tetrahydrobenzoxazole, and chromenone derivatives, to regulate glutamate neurotransmission and treat associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurological and psychiatric disorders are used, then existing therapeutic options are available, but effective modulators of mGluR7 are lacking
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical structures of heterocyclic compounds (changing molecular parameters) to develop selective mGluR7 modulators. This involves modifying substituents, ring structures, and functional groups to optimize binding affinity and selectivity for mGluR7 over other glutamate receptor subtypes, thereby addressing the lack of effective mGluR7-specific treatments
2Reliability
If novel heterocyclic compounds are developed to target mGluR7, then specific therapeutic benefits for glutamate-related disorders are provided, but the complexity of compound synthesis and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the complex heterocyclic molecule into distinct functional modules: core heterocyclic structures (iso-, tetrahydrobenzoxazole, chromenone derivatives) and variable substituent groups. This modular approach allows systematic optimization of different regions independently, simplifying the synthesis and characterization process while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses parameter changes by systematically varying chemical parameters such as substituent types, ring configurations, and functional group positions to optimize compound properties. This structured variation approach enables methodical development of active compounds with desired pharmacological profiles while managing synthesis complexity
Data Source
AI summary
The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 (“mGluR7”). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably mGluR7 subtype of metabotropic glutamate receptors, is involved.